Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 42 of the 44 references it cites were found in a registry or an index.

The RATPAC (Randomised Assessment of Treatment using Panel Assay of Cardiac markers) trial: a randomised controlled trial of point-of-care cardiac markers in the emergency department

Open access
Goodacre, S, Bradburn, M, Fitzgerald, P, Cross, E, Collinson, P, Gray, A, Hall, AS · 2011 · Health Technology Assessment

Abstract

OBJECTIVES: To evaluate the clinical effectiveness and cost-effectiveness of using a point-of-care cardiac marker panel in patients presenting to the emergency department (ED) with suspected but not proven acute myocardial infarction (AMI). DESIGN: Multicentre pragmatic open randomised controlled trial and economic evaluation. SETTING: Six acute hospital EDs in the UK. PARTICIPANTS: Adults presenting to hospital with chest pain due to suspected but not proven myocardial infarction, and no other potentially serious alternative pathology or comorbidity. INTERVENTIONS: Participants were allocated using an online randomisation system to receive either (1) diagnostic assessment using the point-of-care biochemical marker panel or (2) conventional diagnostic assessment without the panel. All tests and treatments other than the panel were provided at the discretion of the clinician. MAIN OUTCOME MEASURES: The primary outcome was the proportion of patients successfully discharged home after ED assessment, defined as patients who had (1) either left the hospital or were awaiting transport home with a discharge decision having been made at 4 hours after initial presentation and (2) suffered no major adverse event (as defined below) during the following 3 months. Secondary outcomes included length of initial hospital stay and total inpatient days over 3 months, and major adverse events (death, non-fatal AMI, life-threatening arrhythmia, emergency revascularisation or hospitalisation for myocardial ischaemia). Economic analysis estimated mean costs and quality-adjusted life-years (QALYs), and then estimated the probability of cost-effectiveness assuming willingness to pay of £20,000 per QALY gained. RESULTS: We randomised 1132 participants to point of care and 1131 to standard care, and analysed 1125 and 1118, respectively [mean age 54.5 years, 1307/2243 (58%) male and 269/2243 (12%) with known coronary heart disease (CHD)]. In the point-of-care group 358/1125 (32%) were successfully discharged compared with 146/1118 (13%) in the standard-care group [odds ratio (OR) adjusted for age, gender and history of CHD 3.81; 95% confidence interval (CI) 3.01 to 4.82, p < 0.001]. Mean length of the initial hospital stay was 29.6 hours versus 31.8 hours (mean difference = 2.1 hours; 95% CI -3.7 to 8.0 hours, p = 0.462), while median length of initial hospital stay was 8.8 hours versus 14.2 hours (p < 0.001). More patients in the point-of-care group had no inpatient days recorded during follow-up (54% vs 40%, p < 0.001), but mean inpatient days did not differ between the two groups (1.8 vs 1.7, p = 0.815). More patients in the point-of-care group were managed on coronary care [50/1125 (4%) vs 31/1118 (3%), p = 0.041]. There were 36 (3%) patients with major adverse events in the point-of-care group and 26 (2%) in the standard-care group (adjusted OR 1.31; 95% CI 0.78 to 2.20, p = 0.313). Mean costs per patient were £1217 with point-of-care versus £1006 with standard care (p = 0.056), while mean QALYs were 0.158 versus 0.161 (p = 0.250). The probability of standard care being dominant (i.e. cheaper and more effective) was 0.888. CONCLUSIONS: Point-of-care testing increases the proportion of patients successfully discharged home and reduces the median (but not mean) length of hospital stay. It is more expensive than standard care and unlikely to be considered cost-effective. TRIAL REGISTRATION: Current Controlled Trials ISRCTN37823923. FUNDING: This project was funded by the NIHR Health Technology Assessment programme and will be published in full in Health Technology Assessment; Vol. 15, No. 23. See the HTA programme website for further project information.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3310/hta15230

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Image 1
CC-BY · From the PDF
FIGURE 2 CONSORT chart showing flow of patients after recruitment.
FIGURE 2 CONSORT chart showing flow of patients after recruitment.CC-BY · From the PDF
FIGURE 3 Duration from arrival to discharge from hospital (all centres).
FIGURE 3 Duration from arrival to discharge from hospital (all centres).CC-BY · From the PDF
FIGURE 4 Duration from arrival to discharge from hospital (individual centres).
FIGURE 4 Duration from arrival to discharge from hospital (individual centres).CC-BY · From the PDF
FIGURE 5 Histograms of number of inpatient days.
FIGURE 5 Histograms of number of inpatient days.CC-BY · From the PDF
© Queen's Printer and Controller of HMSO 2011. This work was produced by Goodacre et al . under the terms of a commissioning contract issued by the Secretary of State for Health.
© Queen's Printer and Controller of HMSO 2011. This work was produced by Goodacre et al . under the terms of a commissioning contract issued by the Secretary of State for Health.CC-BY · From the PDF
FIGURE 6 Cost-effectiveness plane for point-of-care treatment strategy.
FIGURE 6 Cost-effectiveness plane for point-of-care treatment strategy.CC-BY · From the PDF
FIGURE 7 Cost-effectiveness plane for point-of-care treatment strategy, by site.
FIGURE 7 Cost-effectiveness plane for point-of-care treatment strategy, by site.CC-BY · From the PDF
Image 9
CC-BY · From the PDF
Image 10
CC-BY · From the PDF
FIGURE 8 Receiver-operator characteristic curves for GRACE and TIMI scores. (a) TIMI score and 30-day major adverse events (MAEs). (b) GRACE score and 30-day MAEs. (c) TIMI score and 90-day MAEs. (d) GRACE score and 90-day MAEs.
FIGURE 8 Receiver-operator characteristic curves for GRACE and TIMI scores. (a) TIMI score and 30-day major adverse events (MAEs). (b) GRACE score and 30-day MAEs. (c) TIMI score and 90-day MAEs. (d) GRACE score and 90-day MAEs.CC-BY · From the PDF

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Research works printed but not linked: 49

  1. [1]1. Goodacre SW, Bradburn M, Cross E, Collinson PO, Gray A, Hall AS on behalf of the RATPAC research team. he RATPAC trial (Randomised Assessment of Treatment using Panel Assay of Cardiac markers): a randomised controlled trial of point-of-care cardiac markers in the emergency department. Heart 2011;97:190-6.
  2. [3]3. Fitzgerald P, Goodacre SW, Cross E, Dixon S. Cost-efectiveness of point-of-care biomarker assessment for suspected myocardial infarction: the RATPAC trial (Randomised Assessment of Treatment using Panel Assay of Cardiac markers). Acad Emerg Med 2011;18:488-95.
  3. [5]5. Goodacre S, Cross E, Arnold J, Angelini K, Capewell S, Nicholl J. he health care burden of acute chest pain. Heart 2005;91:229-30.
  4. [9]9. Bertrand ME, Simoons ML, Fox KAA, Wallentin LC, Hamm CW, McFadden E, et al. Task Force on the Management of Acute Coronary Syndromes of the European Society for Cardiology. Management of acute coronary syndromes in patients presenting without ST elevation. Eur Heart J 2002;23:1809-40.
  5. [13]13. Collinson PO, Premachandram S, Hashemi K. Prospective audit of incidence of prognostically important myocardial damage in patients discharged from the emergency department. BMJ 2000;320:1702-5.
  6. [15]15. Goodacre S, Nicholl J, Beahan J, Quinney D, Capewell S. National survey of emergency department management of patients with acute, undiferentiated chest pain. Br J Cardiol 2003;10:50-4.
  7. [16]16. Collinson PO, John C, Lynch S, Rao A, Canepa-Anson R, Carson E, et al. A prospective randomised controlled trial of point-of-care testing on the coronary care unit. Ann Clin Biochem 2004;41:397-404.
  8. [19]19. Kendall J, Reeves B, Clancy M. Point of care testing: randomised controlled trial of clinical outcomes. BMJ 1998;316:1052-7.
  9. [21]21. Balk EM, Ioannidis JPA, Salem D, Chew PW, Lau J. Accuracy of cardiac biomarkers to diagnose acute cardiac ischaemia in the emergency department: a meta-analysis. Ann Emerg Med 2001;37:478-94.
  10. [22]22. Fesmire FM, Percy RF, Bardoner JB, Wharton DR, Calhoun FB. Serial creatinine kinase (CK) MB testing during the emergency department evaluation of chest pain: utility of a 2-hour deltaCK-MB of +1.6 ng/ml. Am Heart J 1998;136:237-44.
  11. [23]23. Fesmire FM, Christensen RH, Focy EP, Feintuch TA. Delta creatinine kinase MB outperforms myoglobin at two hours during the emergency department identiication and exclusion of troponin positive non-ST elevation acute coronary syndromes. Ann Emerg Med 2004;44:12-19.
  12. [25]25. Apple FS, Christensen RH, Valdes R, Andriak Aj, Berg A, Duh SH, et al. Simultaneous rapid measurement of whole blood myoglobin, creatinine kinase MB and cardiac troponin I by the triage cardiac panel for detection of myocardial infarction. Clin Chem 1999;45:199-205.
  13. [26]26. Newby LK, Storrow AB, Gibler WB, Garvey JL, Tucker JF, Kaplan AL, et al. Bedside multimarker testing for risk stratiication in chest pain units: the CHECKMATE study. Circulation 2001;103:1832-7.
  14. [34]34. Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, et al. A validated prediction model for all forms of acute coronary syndrome. JAMA 2004;291:2727-33.
  15. [40]40. Goodacre S, Cross E, Lewis C, Nicholl J, Capewell S, on behalf of the ESCAPE Research Team. he ESCAPE cluster randomised trial: efectiveness and safety of chest pain assessment to prevent emergency admissions. BMJ 2007;335:659-62.
  16. [41]41. Goodacre S, Mason S, Arnold J, Angelini K. Psychological morbidity and health-related quality of life of patients assessed on a chest pain observation unit. Ann Emerg Med 2001;38:369-76.
  17. [42]42. Conway Morris A, Caesar D, Gray S, Gray A. he TIMI risk score accurately risk stratiies patients with undiferentiated chest pain presenting to an emergency department. Heart 2006;92:1333-4.
  18. [43]43. Keating L, Benger J, Beetham R, Bateman S, Veysey S, Kendall J, Pullinger R. he PRIMA study: presentation IMA in the emergency department. Emerg Med J 2006;23:764-8.
  19. [44]44. Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, et al. Good research practices for cost-efectiveness analysis alongside clinical trials: he ISPOR RCT-CEA Task Force Report. Value Health 2001;8:521-33.
  20. [60]60. Goodacre S, Cross E, Arnold J, Angelini K, Capewell S, Nicholl J. he health care burden of acute chest pain. Heart 2005;91:229-30.
  21. [61]61. Task Force on the Management of Acute Coronary Syndromes of the European Society for Cardiology. Management of acute coronary syndromes in patients presenting without ST elevation. Eur Heart J 2002;23:1809-40.
  22. [63]63. Goodacre S, Calvert N. Cost efectiveness of diagnostic strategies for patients with acute, undiferentiated chest pain. Emerg Med J 2003;20:429-33.
  23. [64]64. Collinson PO, Premachandram S, Hashemi K. Prospective audit of incidence of prognostically important myocardial damage in patients discharged from the emergency department. BMJ 2000;320:1702-5.
  24. [65]65. Goodacre S, Nicholl J, Dixon S, Cross E, Angelini K, Revill C, et al. Randomised controlled trial and economic evaluation of a chest pain observation unit compared with routine care. BMJ 2004;328:254-7.
  25. [66]66. Goodacre S, Nicholl J, Beahan J, Quinney D, Capewell S. National survey of emergency department management of patients with acute, undiferentiated chest pain. Br J Cardiol 2003;10:50-4.
  26. [67]67. Price CP. Point of care testing. BMJ 2001;322:1285-8.
  27. [68]68. Fesmire FM, Percy RF, Bardoner JB, Wharton DR, Calhoun FB. Serial creatinine kinase (CK) MB testing during the emergency department evaluation of chest pain: utility of a 2-hour deltaCK-MB of +1.6 ng/ml. Am Heart J 1998;136:237-44.
  28. [69]69. Fesmire FM, Christensen RH, Focy EP, Feintuch TA. Delta creatinine kinase MB outperforms myoglobin at two hours during the emergency department identiication and exclusion of troponin positive non-ST elevation acute coronary syndromes. Ann Emerg Med 2004;44:12-19.
  29. [70]70. Ebell MH, Flewelling D, Flynn CA. A systematic review of troponin T and I for diagnosing acute myocardial infarction. J Fam Pract 2000;49:550-6.
  30. [71]71. Balk EM, Ioannidis JPA, Salem D, Chew PW, Lau J. Accuracy of cardiac biomarkers to diagnose acute cardiac ischaemia in the emergency department: a meta-analysis. Ann Emerg Med 2001;37:478-94.
  31. [73]73. McCord J, Nowak RM, McCullough PA, Foreback C, Borzak S, Tokarski G, et al. Ninety- minute exclusion of acute myocardial infarction by use of quantitative point-of-care testing of myoglobin and troponin I. Circulation 2001;104:1483-8.
  32. [74]74. Apple FS, Christensen RH, Valdes R, Andriak Aj, Berg A, Duh SH, et al. Simultaneous rapid measurement of whole blood myoglobin, creatinine kinase MB and cardiac troponin I by the triage cardiac panel for detection of myocardial infarction. Clin Chem 1999;45:199-205.
  33. [75]75. Newby LK, Storrow AB, Gibler WB, Garvey JL, Tucker JF, Kaplan AL, et al. Bedside multimarker testing for risk stratiication in chest pain units: the CHECKMATE Study. Circulation 2001;103:1832-7.
  34. [76]76. Caragher TE, Fernandez BB, Jacobs F, Barr LA. Evaluation of quantitative cardiac biomarker point of care testing in the emergency department. J Emerg Med 2002;22:1-7.
  35. [77]77. Ng SM, Krishnaswamy P, Morissey R, Clopton P, Fitzgerald R, Maisel AS, et al. Ninety- minute accelerated critical pathway for chest pain evaluation. Am J Cardiol 2001;88:611-17.
  36. [79]79. Collinson PO, John C, Lynch S, Rao A, Canepa-Anson R, Carson E, et al. A prospective randomised controlled trial of point-of-care testing on the coronary care unit. Ann Clin Biochem 2004;41:397-404.
  37. [80]80. Kendall J, Reeves B, Clancy M. Point of care testing: randomised controlled trial of clinical outcomes. BMJ 1998;316:1052-7.
  38. [83]83. Panteghini M, Pagani F, Yeo KT, Apple FS, Christenson RH, Dati F, et al. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin Chem 2004;50:327-32.
  39. [84]84. Antman EM, Cohen M, Berninck PJ, Horacek T, Papuchis G, Mautner B, et al. he TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000;284:835-42.
  40. [85]85. Eagle KA, Lim MJ, Dabbous OH, Pieper KS, Goldberg RJ, Van de Werf F, et al. A validated prediction model for all forms of acute coronary syndrome. JAMA 2004;291:2727-33.
  41. [86]86. Goodacre S, Mason S, Arnold J, Angelini K. Psychological morbidity and health-related quality of life of patients assessed on a chest pain observation unit. Ann Emerg Med 2001;38:369-76.
  42. [87]87. Conway Morris A, Caesar D, Gray S, Gray A. he TIMI risk score accurately risk stratiies patients with undiferentiated chest pain presenting to an emergency department. Heart 2006;92:1333-4.
  43. [88]88. Keating L, Benger J, Beetham R, Bateman S, Veysey S, Kendall J, Pullinger R. he PRIMA study: presentation IMA in the emergency department. Emerg Med J 2006;23:764-8.
  44. [93]93. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost efectiveness acceptability curves. Health Econ Lett 2001;10:779-87.
  45. [95]95. Rubin D. Multiple imputation for nonresponse in surveys. New York: J Wiley & Sons; 1987.
  46. [96]96. Briggs A. Probabilistic analysis of cost-efectiveness models: statistical representation of parameter uncertainty. Value Health 2005;8:1-2.
  47. [98]98. Collinson PO, Gaze DC, Bainbridge K, Morris F, Morris B, Price A, et al. Utility of admission cardiac troponin and ischemia modiied albumin (IMA) measurements for rapid evaluation and rule out of suspected acute myocardial infarction in the emergency department. Emerg Med J 2006;23:256-61.
  48. [99]99. Gray A, Goodacre S, Newby D, Masson M, Sampson F, Nicholl J, on behalf of the 3CPO trialists. Efectiveness of non-invasive ventilation in patients with acute severe cardiogenic pulmonary oedema. New Engl J Med 2008;359:142-51.
  49. [101]101. Tsang DM, Owen AM, Collinson PO, Barth JH. Surveys on the use of cardiac markers in the United Kingdom. Ann Clin Biochem 2003;40:138-42.

Cited by

See all 64

Metadata

Authors
Goodacre, S., Bradburn, M., Fitzgerald, P., Cross, E., Collinson, P., Gray, A., & Hall, A.
Affiliations
  • University of Sheffield (GB)
  • St George's Hospital (GB)
  • Edinburgh Royal Infirmary (GB)
Corresponding author
Goodacre, S
Venue
Health Technology Assessment
Published
2011-05
Volume
15
Issue
23
Pages
iii-xi, 1
ISSN
  • 1366-5278 (ISSN-L)
  • 2046-4924
OpenAlex
W1932997227
Cited by
64
References
44
Citations by year
2026: 2 · 2025: 2 · 2024: 3 · 2023: 5 · 2022: 2 · 2021: 3 · 2020: 4 · 2019: 3 · 2018: 4 · 2017: 7 · 2016: 6 · 2015: 6 · 2014: 5 · 2013: 5 · 2012: 7
FWCI
3.74
Type
journal article
Language
en
Open access
Locations
  • Health Technology Assessment (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • UWE Research Repository (UWE Bristol) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
Health Technology Assessment programme (06/302/19)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
  • Health Sciences › Medicine › Emergency Medicine › Emergency and Acute Care Studies
  • Health Sciences › Medicine › Family Practice › Clinical Reasoning and Diagnostic Skills
Keywords
acute myocardial infarction, emergency department, chest pain, diagnostic testing, discharge decisions, major adverse events, cost-effectiveness, quality-adjusted life years, length of hospital stay, clinical effectiveness, coronary artery disease, cardiac arrhythmias, economic evaluation
MeSH terms
Adult, Aged, Cost-Benefit Analysis, Emergency Service, Hospital, Female, Health Status, Humans, Length of Stay, Male, Middle Aged, Myocardial Infarction, Myoglobin, Risk Factors, Sensitivity and Specificity, Troponin, Biomarkers, Patient Satisfaction, Quality-Adjusted Life Years, Point-of-Care Systems, Creatine Kinase, MB Form

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The RATPAC (Randomised Assessment of Treatment using Panel Assay of Cardiac markers) trial: a randomised controlled trial of point-of-care cardiac markers in the emergency department. https://app.cochat.ai/papers/10.3310/hta15230
The paper
Goodacre, S., Bradburn, M., Fitzgerald, P., Cross, E., Collinson, P., Gray, A., & Hall, A. (2011). The RATPAC (Randomised Assessment of Treatment using Panel Assay of Cardiac markers) trial: a randomised controlled trial of point-of-care cardiac markers in the emergency department. Health Technology Assessment. https://doi.org/10.3310/hta15230

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.